Further research has shown that ANGPTL4 expression is significantly upregulated following doxorubicin treatment, whereas epigallocatechin gallate (EGCG) may alleviate FSGS by targeting the HIF-1α/ANGPTL4 pathway to inhibit oxidative stress and podocyte apoptosis (Liu and He, 2019). The gene discussed is ANGPTL4; the disease is focal segmental glomerulosclerosis.